{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T08:23:35Z","timestamp":1774599815861,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,5]],"date-time":"2021-12-05T00:00:00Z","timestamp":1638662400000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100011264","name":"fp7 people: marie-curie actions","doi-asserted-by":"crossref","award":["290080"],"award-info":[{"award-number":["290080"]}],"id":[{"id":"10.13039\/100011264","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100011264","name":"fp7 people: marie-curie actions","doi-asserted-by":"crossref","award":["290080"],"award-info":[{"award-number":["290080"]}],"id":[{"id":"10.13039\/100011264","id-type":"DOI","asserted-by":"crossref"}]},{"name":"instituto de salud carlos iii subdireccio\u0301n general de redes y centros de investigacio\u0301n cooperativa-red de investi-gacio\u0301n cooperativa en enfermedades tropicales","award":["RD16\/0027\/0015, and RD12\/0018\/0005"],"award-info":[{"award-number":["RD16\/0027\/0015, and RD12\/0018\/0005"]}]},{"name":"instituto de salud carlos iii subdireccio\u0301n general de redes y centros de investigacio\u0301n cooperativa-red de investi-gacio\u0301n cooperativa en enfermedades tropicales","award":["RICET: RD16\/0027\/0014"],"award-info":[{"award-number":["RICET: RD16\/0027\/0014"]}]},{"name":"plan nacional","award":["PID2019-109623RB-100 and SAF 2016-79957-R"],"award-info":[{"award-number":["PID2019-109623RB-100 and SAF 2016-79957-R"]}]},{"DOI":"10.13039\/501100011011","name":"junta de andaluc\u00eda","doi-asserted-by":"publisher","award":["BIO-199"],"award-info":[{"award-number":["BIO-199"]}],"id":[{"id":"10.13039\/501100011011","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ministerio de ciencia e innovacio\u0301n","award":["PCT- 010000-2010-4 (NMR), INP-2011-0016-PCT-010000 ACT6 (polarimeter, HPLC, and IR), and PCT-01000-ACT7, 2011-13 (plate reader)]"],"award-info":[{"award-number":["PCT- 010000-2010-4 (NMR), INP-2011-0016-PCT-010000 ACT6 (polarimeter, HPLC, and IR), and PCT-01000-ACT7, 2011-13 (plate reader)]"]}]},{"name":"ministerio de ciencia e innovacio\u0301n","award":["PCT- 010000-2010-4 (NMR), INP-2011-0016-PCT-010000 ACT6 (polarimeter, HPLC, and IR), and PCT-01000-ACT7, 2011-13 (plate reader)]"],"award-info":[{"award-number":["PCT- 010000-2010-4 (NMR), INP-2011-0016-PCT-010000 ACT6 (polarimeter, HPLC, and IR), and PCT-01000-ACT7, 2011-13 (plate reader)]"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Malaria is a global health problem for which novel therapeutic compounds are needed. To this end, a recently published novel family of antiplasmodial macrolides, strasseriolides <jats:bold>A<\/jats:bold>\u2013<jats:bold>D<\/jats:bold>, was herein subjected to in vivo efficacy studies and preclinical evaluation in order to identify the most promising candidate(s) for further development.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Preclinical evaluation of strasseriolides <jats:bold>A<\/jats:bold>\u2013<jats:bold>D<\/jats:bold> was performed by MTT-based cytotoxicity assay in THLE-2 (CRL-2706) liver cells, cardiotoxicity screening using the FluxOR\u2122 potassium assay in hERG expressed HEK cells, LC\u2013MS-based analysis of drug-drug interaction involving CYP3A4, CYP2D6 and CYP2C9 isoforms inhibition and metabolic stability assays in human liver microsomes. Mice in vivo toxicity studies were also accomplished by i.v. administration of the compounds (vehicle: 0.5% HPMC, 0.5% Tween 80, 0.5% Benzyl alcohol) in mice at 25\u00a0mg\/kg dosage. Plasma were prepared from mice blood samples obtained at different time points (over a 24-h period), and analysed by LC-MS to quantify compounds. The most promising compounds, strasseriolides <jats:bold>C<\/jats:bold> and <jats:bold>D<\/jats:bold>, were subjected to a preliminary in vivo efficacy study in which transgenic GFP-luciferase expressing <jats:italic>Plasmodium berghei<\/jats:italic> strain ANKA-infected Swiss Webster female mice (n = 4\u20135) were treated 48\u00a0h post-infection with an i.p. dosage of strasseriolide <jats:bold>C<\/jats:bold> at 50\u00a0mg\/kg and strasseriolide <jats:bold>D<\/jats:bold> at 22\u00a0mg\/kg for four days after which luciferase activity was quantified on day 5 in an IVIS<jats:sup>\u00ae<\/jats:sup> Lumina II imager.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Strasseriolides <jats:bold>A<\/jats:bold>\u2013<jats:bold>D<\/jats:bold> showed no cytotoxicity, no carditoxicity and no drug-drug interaction problems in vitro with varying intrinsic clearance (CLint). Only strasseriolide <jats:bold>B<\/jats:bold> was highly toxic to mice in vivo (even at 1\u00a0mg\/kg i.v. dosage) and, therefore, discontinued in further in vivo studies. Strasseriolide <jats:bold>D<\/jats:bold> showed statistically significant activity in vivo giving rise to lower parasitaemia levels (70% lower) compared to the controls treated with vehicle.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Animal efficacy and preclinical evaluation of the recently discovered potent antiplasmodial macrolides, strasseriolides <jats:bold>A<\/jats:bold>\u2013<jats:bold>D<\/jats:bold>, led to the identification of strasseriolide <jats:bold>D<\/jats:bold> as the most promising compound for further development. Future studies dealing on structure optimization, formulation and establishment of optimal in vivo dosage explorations of this novel compound class could enhance their clinical potency and allow for progress to later stages of the developmental pipeline.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12936-021-03993-8","type":"journal-article","created":{"date-parts":[[2021,12,5]],"date-time":"2021-12-05T21:26:32Z","timestamp":1638739592000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Preclinical evaluation of strasseriolides A\u2013D, potent antiplasmodial macrolides isolated from Strasseria geniculata CF-247,251"],"prefix":"10.1186","volume":"20","author":[{"given":"Frederick","family":"Annang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guiomar","family":"P\u00e9rez-Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caridad","family":"D\u00edaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Gonz\u00e1lez-Men\u00e9ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria","family":"de Pedro Montejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 P\u00e9rez","family":"del Palacio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Tanghe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"P\u00e9rez-Victoria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Cantizani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis M.","family":"Ruiz-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Genilloud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisca","family":"Vicente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4303-5209","authenticated-orcid":false,"given":"Dolores","family":"Gonz\u00e1lez-Pacanowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,5]]},"reference":[{"key":"3993_CR1","doi-asserted-by":"publisher","first-page":"6709","DOI":"10.1021\/acs.orglett.0c01665","volume":"22","author":"F Annang","year":"2020","unstructured":"Annang F, P\u00e9rez-Moreno G, Gonz\u00e1lez-Men\u00e9ndez V, Lacret R, P\u00e9rez-Victoria I, Mart\u00edn J, et al. Strasseriolides A-D, a family of antiplasmodial macrolides isolated from the fungus Strasseria geniculata CF-247251. Org Lett. 2020;22:6709\u201313.","journal-title":"Org Lett"},{"key":"3993_CR2","unstructured":"The Pharmaceutical Research and Manufacturers of America. http:\/\/www.phrma.org\/. Accessed 23 Jun 2021"},{"key":"3993_CR3","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/j.1476-5381.2010.01127.x","volume":"162","author":"JP Hughes","year":"2011","unstructured":"Hughes JP, Rees S, Kalindjian SB, Philpott KL. Principles of early drug discovery. Br J Pharmacol. 2011;162:1239\u201349.","journal-title":"Br J Pharmacol"},{"key":"3993_CR4","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S1359-6446(03)02828-9","volume":"8","author":"H Yu","year":"2003","unstructured":"Yu H, Adedoyin A. ADME\u2013Tox in drug discovery: integration of experimental and computational technologies. Drug Discov Today. 2003;8:852\u201361.","journal-title":"Drug Discov Today"},{"key":"3993_CR5","unstructured":"The New York University School of Medicine. https:\/\/med.nyu.edu\/research\/scientific-cores-shared-resources\/anti-infectives-screening-core\/services. Accessed 23 Jun 2021"},{"key":"3993_CR6","doi-asserted-by":"publisher","first-page":"628","DOI":"10.4236\/abb.2013.45083","volume":"4","author":"J P\u00e9rez","year":"2013","unstructured":"P\u00e9rez J, D\u00edaz C, Salado IG, P\u00e9rez DI, Pel\u00e1ez F, Genilloud O, Vicente F. Evaluation of the effect of compound aqueous solubility in cytochrome P450 inhibition assays. Adv Biosci Biotechnol. 2013;4:628\u201339.","journal-title":"Adv Biosci Biotechnol"},{"key":"3993_CR7","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1177\/1087057106295897","volume":"12","author":"B Krippendorff","year":"2007","unstructured":"Krippendorff B, Lienau P, Reichel A, Huisinga W. Optimizing Classification of drug-drug interaction potential for CYP450 iso-enzymes inhibition assays in early drug discovery. J Biomol Screen. 2007;12:92\u20139.","journal-title":"J Biomol Screen"},{"key":"3993_CR8","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","volume":"99","author":"Y Zhang","year":"2010","unstructured":"Zhang Y, Huo M, Zhou J, Xie S. PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed. 2010;99:306\u201314.","journal-title":"Comput Methods Programs Biomed"},{"key":"3993_CR9","doi-asserted-by":"publisher","first-page":"11468","DOI":"10.1073\/pnas.0503386102","volume":"102","author":"B Franke-Fayard","year":"2010","unstructured":"Franke-Fayard B, Janse CJ, Cunha-Rodrigues M, Ramesar J, B\u00fcscher P, Que I, et al. Murine malaria parasite sequestration: CD36 is the major receptor, but cerebral pathology is unlinked to sequestration. Proc Natl Acad Sci USA. 2010;102:11468\u201373.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3993_CR10","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1113\/jphysiol.1973.sp010086","volume":"228","author":"AC Riches","year":"1973","unstructured":"Riches AC, Sharp JG, Thomas DB, Smith SV. Blood volume determination in the mouse. J Physiol. 1973;228:279\u201384.","journal-title":"J Physiol"},{"key":"3993_CR11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1559-0275-8-12","volume":"8","author":"AHB Wu","year":"2011","unstructured":"Wu AHB. Drug metabolizing enzyme activities versus genetic variances for drug of clinical pharmacogenomic relevance. Clin Proteomics. 2011;8:12\u201320.","journal-title":"Clin Proteomics"},{"key":"3993_CR12","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nature04710","volume":"440","author":"MC Sanguinetti","year":"2006","unstructured":"Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature. 2006;440:463\u20139.","journal-title":"Nature"},{"key":"3993_CR13","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.2174\/138161206777585102","volume":"12","author":"D Thomas","year":"2006","unstructured":"Thomas D, Karle CA, Kiehn J. The cardiac hERG\/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications. Curr Pharm Des. 2006;12:2271\u201383.","journal-title":"Curr Pharm Des"},{"key":"3993_CR14","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2174\/138945009787581203","volume":"10","author":"AU Krettli","year":"2009","unstructured":"Krettli AU, Adebayo JO, Krettli LG. Testing of natural products and synthetic molecules aiming at new antimalarials. Curr Drug Targets. 2009;10:261\u201370.","journal-title":"Curr Drug Targets"},{"key":"3993_CR15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1475-2875-14-8","volume":"14","author":"ET Abay","year":"2015","unstructured":"Abay ET, van der Westuizen JH, Swart KJ, Gibhard L, Lawrence N, Dambuza N, et al. Efficacy and pharmacokinetic evaluation of a novel anti-malarial compound (NP046) in a mouse model. Malar J. 2015;14:8.","journal-title":"Malar J"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-021-03993-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-021-03993-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-021-03993-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,5]],"date-time":"2021-12-05T21:30:05Z","timestamp":1638739805000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-021-03993-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3993"],"URL":"https:\/\/doi.org\/10.1186\/s12936-021-03993-8","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"1 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The relevant ethics approval information has been provided at the \"Methods\" section of the manuscript. No consent to participation was required as this study was not a clinical trial.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The final version of the manuscript has been accepted and approved for publication by all the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"457"}}